Mast Makes Board Appointment
This article was originally published in Scrip
Executive Summary
San Diego-based Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure and stroke has named Peter Greenleaf to its board of directors. Greenleaf currently serves as CEO and a member of the board of Sucampo Pharmaceuticals Inc., which is focused on the development and commercialisation of medicines to meet major unmet medical needs worldwide. He currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Greenleaf is also a member of the board of the Biotechnology Industry Organization (BIO).
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.